Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, August 04, 2022
Curia has appointed Niall Condon as president of its Manufacturing Division. Condon will drive growth and be responsible for operations of Curia’s commercial manufacturing services and products, including API and Drug Product.
read more
Curia made an agreement to provide Curia and its clients a means of access to Touchlight’s doggybone DNA (dbDNA).
read more
Curia Global, Inc. announced expansion plans to its Glasgow, UK facility and provided updates on the ongoing expansion in Albuquerque, NM.
read more
Curia hosted a ground-breaking ceremony to mark the beginning of construction of its expanded campus in Albuquerque, New Mexico.
read more
Curia Global announced the completion of a $4M investment to upgrade its two API aseptic suites in Valladolid, Spain.
read more
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, agreed to acquire Integrity Bio Inc, a privately held formulation and fill-finish organization headquartered in Camarillo, California.
read more
Curia, formerly AMRI, agreed to acquire LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization with facilities in California, Massachusetts, and Texas. LakePharma uses technology ...
read more
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced plans to expand its commercial manufacturing capacity at its Rensselaer, New York facility. The increased capability to flexibly manufacture ...
read more
Tuesday, January 04, 2022
Curia, formerly AMRI, has unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle (LNP) formulation and development for ...
read more
Wednesday, September 22, 2021
CuriRx, Inc., a leading contract research (CRO) and product development organization, announced the launch of their new CuriLytics™ platform with High-Resolution Chemistry Manufacturing and Control (CMC) analytical services. Led by CuriRx's team of ...
read more
Curis has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January, 2015. As previously reported, the extension of exclusivity is associated with a payment of $7....
read more
Tuesday, November 17, 2020
Curis has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI, a component of the National Institutes of Health.
read more
Curium Pharma, a provider of nuclear medicine services, announces the successful completion of its acquisition of Eczacibasi-Monrol Nuclear Products Co. (Monrol), a prominent player in nuclear medicine based in Istanbul, Turkey.
read more
Currax Pharmaceuticals LLC announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union (EU) and European Union Economic Areas (EEA).
read more
Tuesday, September 20, 2016
Custom Pharma Services, a full-service contract development and manufacturing organization (CDMO), has acquired a new building to expand its high containment manufacturing and development operations.
read more